FDA 483 - Plantex Ltd.

An FDA inspection of Plantex Ltd. in Netanya, Israel, revealed significant data integrity and quality control deficiencies. Observations included unauthorized data access and deletion, inadequate test procedures for raw materials and APIs, and insufficient equipment cleaning protocols for microbiological and endotoxin contamination. These issues indicate a lack of robust controls over manufacturing processes and data management.